S&P Futures
4,284.00 -2.50 (-0.06%) Dow Futures
33,972.00 -9.00 (-0.03%) Nasdaq Futures
13,516.25 -7.00 (-0.05%) Russell 2000 Futures
1,998.20 -3.50 (-0.17%) Crude Oil
90.15 -0.35 (-0.39%) Gold
1,769.30 -1.90 (-0.11%)
Tabula Rasa HealthCare, Inc. (TRHC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 5.28 |
| Open | 5.26 |
| Bid | 4.72 x 800 |
| Ask | 5.35 x 1100 |
| Day's Range | 5.10 - 5.33 |
| 52 Week Range | 2.09 - 35.45 |
| Volume | |
| Avg. Volume | 1,695,749 |
| Market Cap | 135.538M |
| Beta (5Y Monthly) | 1.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.83 |
| Earnings Date | Feb 21, 2022 - Feb 25, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.51 |
- PR Newswire
New Study Demonstrates Benefit of Advanced Decision Support in Driving Pharmacist Recommendations to Reduce Medication Risk
A new peer-reviewed study from Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ: TRHC), a leading healthcare technology company advancing the safe use of medications, shows that pharmacist recommendations driven by its unique medication decision support system, MedWise® Science, can help prescribers identify and reduce the levels of potentially inappropriate medications among older adults, reducing the risk of negative cognitive and physical outcomes.
- Business Wire
Indaba Issues Letter to Tabula Rasa’s Independent Directors Regarding Their Apparent Prioritization of the Knowltons’ Interests Over Shareholders’ Interests
SAN FRANCISCO, August 09, 2022--Indaba Capital Management L.P. (together with its affiliates, "Indaba" or "we"), which is the largest shareholder of Tabula Rasa HealthCare Inc. (NASDAQ: TRHC) ("Tabula Rasa" or the "Company") with an ownership interest of approximately 25% of the Company’s outstanding shares, today issued an open letter to the independent members of the Company’s Board of Directors (the "Board"): Samira K. Beckwith, Jan Berger, MD, MJ, Dennis K. Helling, PharmD, ScD, Kathy O’Brie
- Zacks
Does Tabula Rasa Healthcare (TRHC) Have the Potential to Rally 80% as Wall Street Analysts Expect?
The mean of analysts' price targets for Tabula Rasa Healthcare (TRHC) points to a 79.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
